NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 14, 2016

CEO Dr. Lieberman will give a corporate overview and discuss the company’s flagship product candidates designed to treat moderate to severe Parkinson’s disease. > Read More

NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease

First Clinical Efficacy Study Investigating ND0612H Subcutaneously Delivered Liquid Levodopa/Carbidopa for the Treatment of Advanced Parkinson’s Disease.> Read More

NeuroDerm Added to the Nasdaq Biotechnology Index

The Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).> Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.